Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Mabwell Biopharma

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 1

  1. Haoyuan Pharma’s AI Drug Discovery Strategy Meets Its CDMO Platform

    TMTPost reports that Haoyuan Pharma is using its compound inventory and synthesis capabilities to support AI-designed drug candidates through the ABC partnership with Insilico Medicine and Mabwell Biopharma, alongside its MedChemAI screening and customization platform. Haoyuan reported 182,000 molecules in reserve as of June 2026 and operates a Chongqing ADC CDMO facility that opened in March 2025. The report says no disclosed AI-related orders have yet demonstrated commercial demand for this model.

    钛媒体 · 🔥 0

Experience and discussion from the community

Share my Mabwell Biopharma experienceAsk about Mabwell Biopharma

Nobody has shared their experience with Mabwell Biopharma yet.